mirtazapine has been researched along with Liver Diseases in 4 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Liver Diseases: Pathological processes of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mirtazapine treatment rapidly induced a significant reduction in total hepatic B cell numbers, paralleled by a compositional shift in the predominant hepatic B cell subtype from B2 to B1." | 1.62 | The Antidepressant Mirtazapine Rapidly Shifts Hepatic B Cell Populations and Functional Cytokine Signatures in the Mouse. ( Almishri, W; Altonsy, MO; Davis, RP; Jenne, CN; Shaheen, AA; Swain, MG, 2021) |
| "Liver disease (LD) prolongs mirtazapine half-life in humans, but it is unknown if this occurs in cats with LD and healthy cats." | 1.48 | In vivo and in vitro assessment of mirtazapine pharmacokinetics in cats with liver disease. ( Benson, KK; Fitzpatrick, RL; Gustafson, DL; Quimby, JM; Ramirez, D; Sieberg, LG; Wittenburg, LA, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almishri, W | 2 |
| Davis, RP | 1 |
| Shaheen, AA | 2 |
| Altonsy, MO | 1 |
| Jenne, CN | 1 |
| Swain, MG | 2 |
| Fitzpatrick, RL | 1 |
| Quimby, JM | 1 |
| Benson, KK | 1 |
| Ramirez, D | 1 |
| Sieberg, LG | 1 |
| Wittenburg, LA | 1 |
| Gustafson, DL | 1 |
| Sharkey, KA | 1 |
| Dubarek, W | 1 |
| Kucia, K | 1 |
1 review available for mirtazapine and Liver Diseases
| Article | Year |
|---|---|
[Applications and safety of modern antidepressants in patients with liver diseases].
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Cycloprop | 2007 |
3 other studies available for mirtazapine and Liver Diseases
| Article | Year |
|---|---|
The Antidepressant Mirtazapine Rapidly Shifts Hepatic B Cell Populations and Functional Cytokine Signatures in the Mouse.
Topics: Animals; Antidepressive Agents; B-Lymphocyte Subsets; B-Lymphocytes; Cells, Cultured; Cytokines; Hum | 2021 |
In vivo and in vitro assessment of mirtazapine pharmacokinetics in cats with liver disease.
Topics: Animals; Appetite Stimulants; Case-Control Studies; Cat Diseases; Cats; Female; Half-Life; In Vitro | 2018 |
The Antidepressant Mirtazapine Inhibits Hepatic Innate Immune Networks to Attenuate Immune-Mediated Liver Injury in Mice.
Topics: Animals; Antidepressive Agents; Biomarkers; CD4-Positive T-Lymphocytes; Concanavalin A; Cytokines; D | 2019 |